Skip to main content

Table 5 Antifungal agents for preventing mortality in solid organ transplant recipients[20].

From: Incorporating multiple interventions in meta-analysis: an evaluation of the mixed treatment comparison with the adjusted indirect comparison

Treatment Comparison

Mixed Treatment Comparison

Adjusted Indirect Comparison

 

Odds Ratio

95% Credible Interval

Odds Ratio

95% Confidence Interval

Fluconazole vs. Control

0.81

(0.48, 1.37)

0.94

(0.54, 1.63)

Itraconazole vs. Control

0.90

(0.41, 1.99)

0.49

(0.15, 1.56)

Liposomal Amphotericin B vs. Control

0.50

(0.09, 2.33)

0.54

(0.10, 2.52)

Ketoconazole vs. Control

1.83

(0.38, 8.93)

1.66

(0.41, 6.66)

Intraconazole vs. Fluconazole

1.12

(0.52, 2.41)

1.69

(0.58, 5.33)

Liposomal Amphotericin B vs. Fluconazole

0.62

(0.10, 3.17)

0.57

(0.09, 3.39)

Ketoconazole vs. Fluconazole

2.27

(0.43, 12.09)

1.76

(0.39, 7.94)***

Liposomal Amphotericin B vs. Itraconazole

0.55

(0.09, 3.11)

1.10

(0.14, 8.65)**, ***

Ketoconazole vs. Itraconazole

2.03

(0.35, 11.87)

3.38

(0.54, 21.16)***

Ketoconazole vs. Liposomal Amphotericine B

3.68

(0.41, 35.30)

3.07

(0.34, 27.48)***

  1. Bolded text denotes head-to-head meta-analysis evaluations. * Mixed treatment method identifies a significant effect, adjusted indirect comparison does not, adjusted indirect comparison identifies significant effect, mixed treatment comparison does not. ** Direction of effect differs between approaches, ***Important effect size differences.
Back to article page

Trials

ISSN: 1745-6215